Assessment of Vitamin D Effectiveness on Asthma Treatment

Assessment of Vitamin D Injection Dose Adjustment on Vitamin D Deficient Asthmatic Patients Improvement and Treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160813029327N14

Enrollment

Registered

2018-07-17

Start date

2017-10-17

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Disorder of The Airways

Interventions

Intervention group: It includes asthmatic patients with 25(OH)D3 baseline under 20 ng/ml (Vitamin D deficiency). So They need to take blood test in order to evaluate 25(OH)D3 baseline first. After the

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with Moderate to Severe Asthma Under Treatment Asthmatic Patients Vitamin D Deficient Patients

Exclusion criteria

Exclusion criteria: Patients with Infectious Lung Disease Pregnant and Breastfeeding Women Patients with Parathyroid Problems Severe Kidney Disease Severe Liver Disease

Design outcomes

Primary

Measure	Time frame
25(OH)D3 Baseline. Timepoint: Assessment of 25(OH)D3 Baseline before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Blood Test.;Forced Expiratory Volume In First Second. Timepoint: Assessment of Forced Expiratory Volume In First Second, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.;Forced Vital Capacity. Timepoint: Assessment of Forced Vital Capacity, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.;Proportion of a Person's Vital Capacity that He Is Able to Expire in The First Second of Forced Expiration. Timepoint: Assessment of Proportion of a Person's Vital Capacity that He Is Able to Expire in The First Second of Forced Expiration, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.	—

Measure

Time frame

25(OH)D3 Baseline. Timepoint: Assessment of 25(OH)D3 Baseline before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Blood Test.;Forced Expiratory Volume In First Second. Timepoint: Assessment of Forced Expiratory Volume In First Second, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.;Forced Vital Capacity. Timepoint: Assessment of Forced Vital Capacity, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.;Proportion of a Person's Vital Capacity that He Is Able to Expire in The First Second of Forced Expiration. Timepoint: Assessment of Proportion of a Person's Vital Capacity that He Is Able to Expire in The First Second of Forced Expiration, before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: Spirometry Device.

—

Secondary

Measure	Time frame
Quality of Life. Timepoint: Assessment of Quality of Life of The Patient before Starting The Intervention and Again 2 Months After The First Injection of Vitamin D Ampoule. Method of measurement: St. George's Respiratory Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Rajabi

Islamic Azad University

mehdirj@aol.co.uk+98 21 2264 0051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026